Literature DB >> 14512703

Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.

Ottorino Pozzi1, Paola Misiano, Geoffrey D Clark, Luciano Visentin.   

Abstract

The CB1/CB2 receptor agonist WIN 55212-2 (0.75 mg/kg, i.v.) caused a significant reduction in neurogenic plasma extravasation induced by electrical stimulation of the saphenous nerve in anesthetized rats; WIN 55212-2 at 2.5-10 mg/kg, s.c., also produced a significant reduction in the carrageenan-induced paw edema in conscious rats. The selective CB1 antagonist SR 141716A (0.075-0.75 mg/kg i.v.) antagonized the WIN 55212-2 effects in the plasma extravasation model and antagonized the WIN 55212-2 (2.5 mg/kg, s.c.)-induced decreases in rectal temperature and increases in tail-flick latencies. However, SR 141716A (10 mg/kg, p.o.) failed to antagonize the effects of Win 55212-2 (2.5 mg/kg, s.c.) in the carrageenan model, suggesting that cannabinoid receptors found in the periphery may be able to modulate inflammatory processes in rats. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512703     DOI: 10.1159/000072669

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

1.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

2.  The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding.

Authors:  Sherin Y Boctor; Joe L Martinez; Wouter Koek; Charles P France
Journal:  Eur J Pharmacol       Date:  2007-06-13       Impact factor: 4.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.